Abstract:Polycystic ovary syndrome (PCOS) is a one of the most common endocrine disorders, with a prevalence rate of 5–10% in reproductive aged women. It’s characterized by (1) chronic anovulation, (2) biochemical and/or clinical hyperandrogenism, and (3) polycystic ovarian morphology. PCOS has significant clinical implications and can lead to health problems related to the accumulation of adipose tissue, such as obesity, insulin resistance, metabolic syndrome, and type 2 diabetes. There is also evidence that PCOS patients are at higher risk of cardiovascular diseases, atherosclerosis, and high blood pressure. Several studies have reported the association between polycystic ovary syndrome (PCOS) and low-grade chronic inflammation. According to known data, inflammatory markers or their gene markers are higher in PCOS patients. Correlations have been found between increased levels of C-reactive protein (CRP), interleukin 18 (IL-18), tumor necrosis factor (TNF-α), interleukin 6 (IL-6), white blood cell count (WBC), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1α (MIP-1α) in the PCOS women compared with age- and BMI-matched controls. Women with PCOS present also elevated levels of AGEs and increased RAGE (receptor for advanced glycation end products) expression. This chronic inflammatory state is aggravating by obesity and hyperinsulinemia. There are studies describing mutual impact of hyperinsulinemia and obesity, hyperandrogenism, and inflammatory state. Endothelial cell dysfunction may be also triggered by inflammatory cytokines. Many factors involved in oxidative stress, inflammation, and thrombosis were proposed as cardiovascular risk markers showing the endothelial cell damage in PCOS. Those markers include asymmetric dimethylarginine (ADMA), C-reactive protein (CRP), homocysteine, plasminogen activator inhibitor-I (PAI-I), PAI-I activity, vascular endothelial growth factor (VEGF) etc. It was also proposed that the uterine hyperinflammatory state in polycystic ovary syndrome may be responsible for significant pregnancy complications ranging from miscarriage to placental insufficiency. In this review, we discuss the most importance evidence concerning the role of the process of chronic inflammation in pathogenesis of PCOS.

[Clinical implications of polycystic ovary syndrome]

The Importance of Diagnosing the Polycystic Ovary Syndrome

PCOS: metabolic impact and long-term management

Polycystic Ovary Syndrome (PCOS): Bridging Gaps in Understanding, Diagnosis, and Management

Cardiometabolic consequences of PCOS

Type 2 Diabetes Mellitus in Patients With Polycystic Ovary Syndrome

Epidemiology, diagnosis, and management of polycystic ovary syndrome

Polycystic ovary syndrome. Long term sequelae and management

Impact of Polycystic Ovary Syndrome on Pregnancy Outcome

Polycystic ovary syndrome: Endometrial markers

Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease

Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature

Psychiatric disorders related to polycystic ovary syndrome

Approach to the Patients with Polycystic Ovary Syndrome

Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome

Polycystic ovary syndrome: the influence of environmental and genetic factors

The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment

The Invisible Struggle: The Psychosocial Aspects of Polycystic Ovary Syndrome

[Long-term consequences of polycystic ovary syndrome]

Polycystic ovary syndrome as a metabolic disease

Chronic Low Grade Inflammation in Pathogenesis of PCOS